Effect of levamisole on immunological parameters in patients with systemic lupus erythematosus. 1980

O Scherak, and J S Smolen, and E J Menzel, and M Kojer, and G Kolarz

Parameters of cell-mediated and humoral immunity were examined in 8 patients with clinically inactive SLE undergoing levamisole treatment. Lymphocyte transformation with PHA and PMW was temporarily increased in the first month of therapy; at the same time absolute numbers of peripheral blood lymphocytes, T cells and B cells increased slightly. However, these differences were not significant statistically. In 1 patient with a diminished percentage of T cells and an increased percentage of B cells, levamisole induced normalization. Antibodies to DNA decreased in 6 patients, while titres of ANA decreased only in one patient. Serum levels of C1q and C3 increased in 7 and 3 patients, respectively. Four patients were treated with levamisole for 12 months, during which time there was neither clinical exacerbation nor deterioration of renal function and the concomitant corticosteroid therapy could be reduced.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D007978 Levamisole An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6) L-Tetramisole,Levotetramisole,Decaris,Dekaris,Levamisole Hydrochloride,Solaskil,Hydrochloride, Levamisole
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008934 Mitogens Substances that stimulate mitosis and lymphocyte transformation. They include not only substances associated with LECTINS, but also substances from streptococci (associated with streptolysin S) and from strains of alpha-toxin-producing staphylococci. (Stedman, 25th ed) Mitogen,Phytomitogen,Phytomitogens
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D004247 DNA A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine). DNA, Double-Stranded,Deoxyribonucleic Acid,ds-DNA,DNA, Double Stranded,Double-Stranded DNA,ds DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000974 Antibodies, Antinuclear Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease. Anti-DNA Antibodies,Antibodies, Anti-DNA,Antinuclear Antibodies,Antinuclear Autoantibodies,Antinuclear Autoantibody,Antinuclear Factors,Antinuclear Antibody,Antinuclear Factor,Anti DNA Antibodies,Antibody, Antinuclear,Autoantibody, Antinuclear,Factor, Antinuclear

Related Publications

O Scherak, and J S Smolen, and E J Menzel, and M Kojer, and G Kolarz
January 1981, Terapevticheskii arkhiv,
O Scherak, and J S Smolen, and E J Menzel, and M Kojer, and G Kolarz
September 1979, Annals of allergy,
O Scherak, and J S Smolen, and E J Menzel, and M Kojer, and G Kolarz
April 1982, Arthritis and rheumatism,
O Scherak, and J S Smolen, and E J Menzel, and M Kojer, and G Kolarz
August 1976, Annals of allergy,
O Scherak, and J S Smolen, and E J Menzel, and M Kojer, and G Kolarz
August 2017, The Indian journal of medical research,
O Scherak, and J S Smolen, and E J Menzel, and M Kojer, and G Kolarz
April 1986, Immunitat und Infektion,
O Scherak, and J S Smolen, and E J Menzel, and M Kojer, and G Kolarz
January 1980, Allergologia et immunopathologia,
O Scherak, and J S Smolen, and E J Menzel, and M Kojer, and G Kolarz
April 1981, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
O Scherak, and J S Smolen, and E J Menzel, and M Kojer, and G Kolarz
January 1973, Dermatologica,
O Scherak, and J S Smolen, and E J Menzel, and M Kojer, and G Kolarz
January 1978, Panminerva medica,
Copied contents to your clipboard!